However, amylin lacks potency in terms of weight loss and glucose tolerance, and only one amylin analogue, pramlintide, has been FDA-approved and only as an add-on to insulin in people with diabetes (type 1 and 2). This evidence concerns the gene IAPP and diabetes mellitus.